EPO and infarction: Past studies have demonstrated nontherapeutic effects of upregulating erythropoietin (EPO), another HIF-1 alpha gene target, in the hippocampus and cerebral cortex, including BBB permeability prevention, brain edema reduction, decreased infarction volume, and post-HBOT neurobehavioral improvement [152,153].